Evelo Biosciences Inc (EVLO) USD0.001

Sell:$0.00Buy:$0.00No change

Prices delayed by at least 15 minutes
Sell:$0.00
Buy:$0.00
Change:No change
Prices delayed by at least 15 minutes
Sell:$0.00
Buy:$0.00
Change:No change
Prices delayed by at least 15 minutes

Company Information

About this company

Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing a class of oral medicines that act on immune cells in the small intestine with systemic effects. Its small intestinal axis (SINTAX) is the network of connections that links the small intestine and the rest of the body. Immune cells and other cells in the small intestine act as sentinels and are constantly sensing the contents of the gut. Depending on what is sensed, these cells relay messages from the gut to the rest of the body that modulate systemic immunity. Its orally delivered product candidates are pharmaceutical compositions of specific single strains of commensal microbes or the extracellular vesicles (EVs) they shed.

Key people

Craig R. Jalbert
President, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer, Company Secretary, Director
Mark W. Bodmer
Chief Scientific Officer, President of Research and Development
Daniel S. Char
General Counsel, Secretary
Duncan McHale
Chief Medical Officer
Mark Plinio
Chief Commercial Officer
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US2997342025
  • Market cap
    $9,470.00
  • Employees
    66
  • Shares in issue
    18.93m
  • Exchange
    Over The Counter
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.